Kanna vs Ketamine: How They Differ in Use, Legality, and Effects

kannaketaminecomparisonmental wellnesssupplement vs prescription

Kanna and ketamine end up in the same conversations surprisingly often — partly because both attract interest from people looking for mental wellness options beyond conventional antidepressants, and partly because both carry an aura of novelty compared to mainstream psychiatry. In almost every practical sense, however, they are very different substances. This comparison explains how they differ in mechanism, effects, legal status, clinical evidence, and appropriate use.

What They Are

Kanna (Sceletium tortuosum) is a succulent plant native to South Africa. Its active compounds — primarily mesembrine and mesembrenone — are alkaloids that appear to act as mild serotonin reuptake inhibitors and PDE4 inhibitors. Kanna is sold as a dietary supplement in the US. It is legal, unscheduled, and available without a prescription.

Ketamine is a synthetic compound first developed in the 1960s as an anesthetic. It is a Schedule III controlled substance under federal law. In a psychiatric context, it is used either as IV/IM racemic ketamine (off-label, self-pay at licensed clinics) or as Spravato (esketamine nasal spray, FDA-approved for treatment-resistant depression). Ketamine requires a prescription and clinical supervision — it cannot be legally purchased or used outside a medical setting for psychiatric purposes.

Mechanism of Action

The two substances act through largely different pathways, which is important context for understanding their effects and risks.

Kanna’s primary mechanism involves inhibiting the serotonin transporter — the same general mechanism as SSRI antidepressants, though the potency and pharmacological specifics differ considerably. It also inhibits PDE4, an enzyme involved in neuroinflammation and cognition. The result is a mild, relatively gentle shift in mood and anxiety for most users at typical supplemental doses.

Ketamine’s primary mechanism involves antagonism of NMDA receptors (glutamate receptors), which produces dissociation and altered consciousness. It also triggers rapid downstream effects on synaptic plasticity and BDNF that are thought to contribute to its antidepressant effects. This is a fundamentally different pathway — ketamine does not primarily work on serotonin. Its effects are significantly more intense and shorter-lasting than kanna’s at therapeutic doses.

Effects and the Subjective Experience

This is where the practical difference is most apparent.

A typical kanna experience at supplemental doses (25-50mg of a standardized extract) involves a mild lift in mood, reduced anxiety, and a sense of calm sociability. Many users compare it to a moderate cup of coffee in terms of the subtlety of the effect — noticeable but not dramatic. Higher doses can produce more pronounced effects, including mild euphoria.

A ketamine infusion is a meaningfully altered experience. At dissociative doses used in psychiatric treatment, patients often experience detachment from the body, altered perception of time and space, visual phenomena, and a profound shift in perspective that can feel meaningful or unsettling. The experience typically lasts 45 minutes to an hour for IV administration and requires clinical supervision.

These are not different points on the same spectrum — they are qualitatively different categories of experience.

This is perhaps the clearest difference between the two.

Kanna is not scheduled under the Controlled Substances Act. It can be purchased legally in the US as a dietary supplement. No prescription is required. Quality varies by manufacturer because supplements do not require FDA pre-market approval under DSHEA.

Ketamine is a Schedule III controlled substance. It is legal to prescribe and administer by licensed practitioners for legitimate medical purposes. It is not legal to possess without a prescription, and administering it outside a licensed medical setting is a federal criminal matter. For reference, the DEA’s drug scheduling information is available at DEA.gov.

Evidence Base

The evidence bases are also in different leagues — not because kanna is ineffective, but because ketamine has been the subject of far more formal clinical investigation.

Ketamine’s antidepressant effects are documented in multiple peer-reviewed trials published in major journals. Spravato’s approval for treatment-resistant depression (ICD-10 F33.2 or F32.9) and acute suicidal ideation is based on the FDA’s review of Phase 3 clinical trial data. The off-label use of IV ketamine has a growing evidence base from academic medical centers, though it does not have the same regulatory endorsement.

Kanna’s evidence base consists of smaller studies, primarily using the Zembrin standardized extract. Results are promising for mild anxiety and stress reactivity, but the scale of evidence does not support claims of equivalence to prescription treatments. This is not unusual for dietary supplements — it reflects both the regulatory framework and the economics of supplement research.

Who Uses Each, and Why

Kanna tends to attract people who are dealing with everyday stress, mild anxiety, or a sense that their mood could use support, and who prefer a gentler, accessible, plant-based option. It is also used by some people as a complement to therapy or other wellness practices.

Ketamine tends to attract people who have treatment-resistant depression (diagnosed, typically with failed medication trials), PTSD, or other significant psychiatric conditions that have not responded to standard treatments. It is a clinical intervention for a clinical problem, used when less intensive options have not worked.

These are different populations with different needs, and the appropriate choice — if any — depends heavily on individual circumstances that only a clinician can assess.

For questions about which options might be appropriate for your situation, reach out here and we will point you toward the right resources.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.